Frazier Life Sciences
Overview
Frazier Life Sciences is a healthcare investment firm that invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Parabilis Medicines | Jan 2026 | Series F | Co-investor |
| Fog Pharmaceuticals | Jan 2026 | Series F | Co-investor |
| Alentis Therapeutics | Nov 2024 | Series D | Co-investor |
| MBX Biosciences | Aug 2024 | Series C | Co-investor |
| Day One Biopharmaceuticals | Aug 2024 | Private Placement | Co-investor |
For institutional investors. Book with your work email.
Key People
Patrick Heron
Managing Partner
Daniel Estes
General Partner
Jamie B.
General Partner And Portfolio Manager
Aditya Kohli
Venture Partner
James Li
Venture Partner
Mitchell Gold
Venture Partner
Stanford Peng
Venture Partner
Tao Fu
Venture Partner
Adam Simpson
Executive Partner
Anna H. Chen
Partner
Joe Cabral
Partner
Jennifer Martin
Chief Financial Officer and Partner
Ailsa Dalgliesh
Head Of Investor Relations
Chris Aakre
Principal Of Company Creation
Lauren Mifflin
Principal, Company Creation
Gordon Empey
Partner & General Counsel
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Frazier Life Sciences based?
Frazier Life Sciences is headquartered in Palo Alto, California, United States.
When was Frazier Life Sciences founded?
Frazier Life Sciences was founded in 2005.
How many portfolio companies does Frazier Life Sciences have?
Frazier Life Sciences has 48 portfolio companies in Caplight's dataset.
What are some companies in Frazier Life Sciences's portfolio?
Portfolio companies visible on Caplight include Parabilis Medicines, Fog Pharmaceuticals, Alentis Therapeutics, MBX Biosciences, Day One Biopharmaceuticals.
What was Frazier Life Sciences's most recent investment shown here?
Frazier Life Sciences's most recent investment in this portfolio sample was in Parabilis Medicines in 2026.
What sectors does Frazier Life Sciences focus on?
Frazier Life Sciences focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Energy & Sustainability, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does Frazier Life Sciences focus on?
Frazier Life Sciences typically invests at the MultiStage stage.
What is Frazier Life Sciences's AUM?
Frazier Life Sciences's assets under management are estimated between $7.0B and $7.1B.